If Approved -- FDA Drug Labeling Could Decide Ultimate Success of MannKind's Afrezza
The U.S. Food and Drug Administration's delay in completing its review of MannKind Corp .'s ultra rapid-acting insulin therapy, called Afrezza , by the expected action date of January 16 has added to uncertainty over the commercial prospects of this experimental inhaled insulin.
Join the discussion below, or Read more at BNET.
#1 Feb 13, 2010
The FDA needs to speed their process up. I used Exubera for 2 years and recently ran out. Which meant I went back to 4 injections a day and blood sugars that have been crazy. Inhaled insulin was my cure. It allowed me to take 1 LT injection a day and kept my HgA1c at 6 . Now it is at 8 because I can't get regulated back on St injections. I will be first in line to try Afrezza..it is a fantastic product and I cant wait for it.
Add your comments below
|Its inhaled insulin will succeed where Big Phar... (Jun '09)||Jun '09||Jolly Rancher||1|
Find what you want!
Search MannKind Forum Now
Copyright © 2017 Topix LLC